KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) EPS (Weighted Average and Diluted) (2020 - 2026)

Aquestive Therapeutics has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at -$0.27 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 42.11% year-over-year to -$0.27; the TTM value through Dec 2025 reached -$0.79, down 51.92%, while the annual FY2025 figure was -$0.78, 52.94% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.27 at Aquestive Therapeutics, down from -$0.14 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.11 in Q1 2023 and troughed at -$0.73 in Q4 2021.
  • A 5-year average of -$0.22 and a median of -$0.21 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 371.43% in 2021 and later soared 134.38% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.73 in 2021, then soared by 69.86% to -$0.22 in 2022, then soared by 40.91% to -$0.13 in 2023, then crashed by 46.15% to -$0.19 in 2024, then tumbled by 42.11% to -$0.27 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for AQST at -$0.27 in Q4 2025, -$0.14 in Q3 2025, and -$0.14 in Q2 2025.